Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab (PROVETTA)

Azienda Ospedaliero, Universitaria Pisana

Status: Unknown

Conditions: Metastatic Colorectal Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01363739

3108

Details and patient eligibility

About

-1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients. The present study aims to prospectively evaluate the predictive role of this polymorphism in metastatic colorectal patients receiving the same treatment.

Enrollment: 265 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Histologically confirmed colorectal adenocarcinoma;
• Measurable metastatic disease according to RECIST criteria;
• Patients receiving BV plus FOLFIRI as first-line treatment;
• Written informed consent;
• Availability of blood samples for genetic analysis.-

Exclusion Criteria: